INVO Bioscience, Inc. (INVO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on September 18, 2024, covering events occurring on September 12, 2024. INVO Bioscience, Inc. (the "Company") entered into a Fourth Amendment to its previously announced Agreement and Plan of Merger with NAYA Biosciences, Inc. ("NAYA"). The filing details the extension of the merger deadline and significant restructuring of the transaction consideration.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial activity disclosed is a capital transaction related to the merger:
- Series A Preferred Stock Sale: NAYA purchased 27,500 shares of the Company's Series A Preferred Stock for $137,500 on September 16, 2024.
- Additional Purchase Option: NAYA retains the option to purchase up to an additional 72,500 shares of Series A Preferred Stock for an aggregate of $362,500 prior to or concurrently with the merger closing.
- Merger Consideration Structure: The revised deal structure involves the Company issuing common stock representing no more than 19.9% of its outstanding shares immediately before the merger, plus newly designated Series C Convertible Preferred Stock.
Material Changes and Restructuring
Significant changes to the original merger agreement include:
- Deadline Extension: The termination date for the Merger Agreement was extended to October 14, 2024.
- Closing Timeline: The parties aim to close the merger on or about October 1, 2024, but no later than October 14, 2024.
- Consideration Restructuring: The deal now includes a hybrid payment of common stock and Series C Convertible Preferred Stock. Upon conversion of the Series C shares (subject to stockholder approval), the resulting shares will represent approximately 60.1% of the Company's outstanding common stock.
- Lender Allocation: NAYA agreed to transfer 85% of the Common Stock Payment Shares to Five Narrow Lane LP ("FNL"), a secured lender of NAYA.
- Waivers: Both parties waived prior breaches of the Merger Agreement.
Outlook, Risks, and Contingencies
Management has committed to using best efforts to consummate the transactions. Key contingencies and future obligations include:
- Stockholder Approval: The Company must hold a stockholder meeting within 120 days of the merger closing (potentially later if SEC comments require proxy restatement) to approve the issuance of shares upon conversion of the Series C Preferred Stock.
- SEC Filings: The Company must file a proxy statement within 35 days of the merger closing and a resale registration statement as soon as possible after closing.
- Compliance: The revised merger structure must comply with Nasdaq listing and governance rules.
- Risk of Termination: The merger remains subject to termination if the October 14, 2024 deadline is not met or if other exceptions apply.
Investor Verification Checklist
- Verify the execution of the "A&R Merger Agreement" (Amended and Restated) to confirm the final terms of the consideration.
- Monitor the filing of the proxy statement for the stockholder meeting to approve the Series C conversion.
- Confirm whether NAYA exercises the option to purchase the additional 72,500 shares of Series A Preferred Stock.
- Review the Certificate of Designations for the Series C Convertible Preferred Stock to understand conversion mechanics and rights.
- Track the status of the merger closing relative to the October 14, 2024 deadline.